Clinical trial
12 Months-observation of Patients Treated for Hidradenitis Suppurativa, With High Cardiovascular Risk or Established Coronary Plaque: A Prospective Monocentric Study - the HOPE Study
NCT07454889 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 12 Months-observation of Patients Treated for Hidradenitis Suppurativa, With High Cardiovascular Risk or Established Coronary Plaque: A Prospective Monocentric Study - the HOPE Study
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- March 31, 2027
- Enrollment
- 34 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.